Medizinische Universität Graz - Research portal
Selected Publication:
WALMRATH, D; GRIMMINGER, F; OLSCHEWSKI, H; SEEGER, W.
ROLE OF PGE(1) AND PGI(2) IN THE THERAPEUTIC MANAGEMENT OF PULMONARY-HYPERTENSION
MED WELT. 1993; 44(10): 610-618.
Web of Science
- Co-authors Med Uni Graz
- Olschewski Horst
- Altmetrics:
- Abstract:
- The vasodilatory prostanoids PGE1 and PGI2 Offer as therapeutic agents for patients with critical pulmonary hypertension and right heart decompensation under intensive care conditons. By use of chronic ambulatory PGI2 infusion, patients with primary pulmonary hypertension may be bridged for (heart-)lung transplantation. In patients with ARDS and sepsis, vasodilatory prostanoids may possibly increase oxygen delivery and influence altered blood flow in microcirculation and thereby prevent or reduce multiple organ failure. The prostanoids PGE1 and PGI2 possess strong vasodilatory potency in the pulmonary circulation nevertheless indications are rare for intravenous application due to limited pulmonary and intrapulmonary selectivity. PGE1 and PGI2 decline systemic vascular resistance (limited pulmonary selectivity) and general pulmonary vasodilatation induce or enhance ventilation-perfusion mismatch accompanied by an impairment of gas exchange conditions (limited intrapulmonary selectivity). Application of the vasodilatative prostanoids via the transbronchial route (aerosol) may offer as future perspective to achieve pulmonary and intrapulmonary selectivity.
- Find related publications in this database (Keywords)
- VASODILATORY PROSTANOIDS
- PULMONARY HYPERTENSION
- ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
- SEPSIS